10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment.
Muscle-invasive urothelial carcinoma is treated with cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy and urinary diversion, or by trimodality bladder preservation (maximal resection plus chemoradiation) in suitable patients. Perioperative immunotherapy has entered practice: adjuvant nivolumab after cystectomy (CheckMate 274), which lengthened disease-free survival while its five-year overall survival difference was not statistically significant (hazard ratio 0.83, 95% confidence interval 0.67 to 1.02), and durvalumab with neoadjuvant chemotherapy and after surgery (NIAGARA), which improved overall survival. Enfortumab vedotin with pembrolizumab before and after cystectomy was approved by the FDA on 21 November 2025 for patients ineligible for cisplatin (EV-303) and on 10 July 2026 for all candidates for cystectomy (EV-304), and durvalumab with enfortumab vedotin was approved on 13 November 2026 for patients who are ineligible for or have refused cisplatin (VOLGA). For metastatic disease, enfortumab vedotin with pembrolizumab nearly doubled survival compared with platinum chemotherapy (EV-302) and became the standard first-line treatment in 2023; erdafitinib is used for FGFR3-altered tumours, and platinum chemotherapy followed by avelumab maintenance remains an option. Molecular subtypes (luminal, basal) and circulating tumour DNA are being used to select who needs adjuvant treatment.
| Setting | Approach | Guideline |
|---|---|---|
| Muscle-invasive, cisplatin-eligible | Neoadjuvant cisplatin-based chemotherapy (dose-dense MVAC or gemcitabine-cisplatin) with durvalumab (NIAGARA), then radical cystectomy with lymph node dissection and adjuvant durvalumab; or enfortumab vedotin plus pembrolizumab before and after cystectomy (EV-304, FDA 10 July 2026); adjuvant nivolumab for high-risk residual disease (CheckMate 274). | not mapped |
| Muscle-invasive, ineligible for or declining cisplatin | Enfortumab vedotin plus pembrolizumab before and after radical cystectomy (EV-303, FDA 21 November 2025), or durvalumab plus enfortumab vedotin before cystectomy then durvalumab alone after it (VOLGA, FDA 13 November 2026). | not mapped |
| Bladder preservation | Maximal transurethral resection followed by chemoradiation, with salvage cystectomy for recurrence, in patients with unifocal tumours and no carcinoma in situ or in those unfit for surgery. | not mapped |
| Metastatic, first line | Enfortumab vedotin plus pembrolizumab (EV-302); gemcitabine-platinum followed by avelumab maintenance where the combination is unavailable. | not mapped |
| Later lines | Erdafitinib for FGFR3 alterations; platinum chemotherapy or enfortumab vedotin if not given first line; clinical trials. | not mapped |